

Working Title: Promoting Mobility and Healthy Ageing in Men: A Narrative Review

Authors: Peter R. Ebeling, MBBS, MD, FRACP, <https://orcid.org/0000-0002-2921-3742>¹; Flavia Cicuttini, MBBS, PhD, MSc, FRACP, <https://orcid.org/0000-0002-8200-1618>²; David Scott, PhD, BHM, PhD, <https://orcid.org/0000-0001-5226-1972>³; Graeme Jones, MBBS, PhD, FRACP, <https://orcid.org/0000-0002-9814-0006>⁴

Affiliations: ¹School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia; ²School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia; ³Australian Institute for Musculoskeletal Science, The University of Melbourne, Melbourne, Australia; ⁴Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia

Address for correspondence:

Peter R. Ebeling, MBBS, MD, FRACP
Professor of Medicine
School of Clinical Sciences at Monash Health
Monash University
Level 5 / Block E,
Monash Medical Centre
246 Clayton Road
Clayton, VIC 3168
Australia
Phone: +61 3 8572 2570
E-mail: peter.ebeling@monash.edu

ACKNOWLEDGMENTS

Medical writing support was provided by Diane Sloan, PharmD, of Peloton Advantage, LLC, and was funded by an unrestricted educational grant from Pfizer.

CONFLICT OF INTEREST STATEMENT

PRE has received research funding from Alexion, Amgen, and Eli Lilly and speaker honoraria from Amgen. FC declares that they have no conflict of interest. DS has received a speaker honorarium from Amgen. GJ declares that they have no conflict of interest.

ABSTRACT (Word limit: 150–250; Current word count: 250)

Purpose: Limitations in mobility are increasingly recognized as a major public health problem due to an ageing population and growing number of older individuals affected by disabling comorbidities. Despite increasing numbers and debilitating consequences, there are no guidelines providing recommendations on strategies to maintain mobility for healthy ageing among older men. This narrative review aims to fill this literature gap.

Methods: PubMed, Scopus, and Google Scholar databases were searched using predefined search terms. Primary studies, exploratory analyses, cross-sectional surveys, meta-analyses, evidence-based clinical reviews, and guidelines from nationally recognized societies focusing on mobility in older men and key elements including bone, muscle and joint health, and balance were selected.

Results: Several modifiable and nonmodifiable risk factors have been reported in the literature that impact bone, muscle, and joint health and predispose older men to falls and fractures. The most common conditions impacting bones, muscles, and joints are osteoporosis, sarcopenia, and osteoarthritis, respectively. In addition to being key contributors to disability in the elderly, these conditions are all associated with a higher mortality risk. Although more studies are required, current evidence supports the use of various nonpharmacological (mainly exercise and nutrition) and/or pharmacological treatment modalities to help prevent and/or reverse these conditions.

Conclusions: Incorporating lifestyle interventions involving exercise and nutrition at a younger age can help prevent the age-related, progressive deterioration in bones, muscles, and joints that can reduce mobility in later life. Established barriers to

physical activities (e.g., poor health, social isolation) in men are important to consider for optimizing outcomes.

Keywords: Ageing, falls, male mobility, osteoporosis, sarcopenia

MINI ABSTRACT

Maintaining mobility is an important aspect of health and well-being in older men.

This literature review describes several modifiable and nonmodifiable risk factors impacting bone, muscle, and joint health. Exercise and nutritional interventions may help to prevent the progressive deterioration in bones, muscles, and joints impacting mobility in later life.

(Word count limit: 10,000; Current count: 4,773)

INTRODUCTION

Mobility, defined as the ability to move about independently and safely in one's environment, is an important component of health and quality of life among older adults [1]. However, 40% of individuals reported mobility limitations in a recent nationally representative survey of insured older adults in the United States (US). The prevalence of mobility limitations assessed as severe or moderate were 21.4% and 18.4%, respectively, among the study sample of 15,989 older adults with Medicare supplemental insurance plans (survey responses were weighted based on demographic, socioeconomic, and clinical variables to adjust for potential bias associated with survey response and stratified sampling to increase generalizability and create a nationally representative study sample) [2]. The authors reported that individuals with mobility limitations were more likely to suffer from depression and less likely to have ambitious goals, resilience, or social support [2].

A previous survey of community-dwelling older adults enrolled in Medicare demonstrated that mobility limitations were common (present in 45% of the population) and strongly associated with development of future functional disability/loss of independence and increased healthcare care expenditures and utilization [3]. Furthermore, mobility (defined as self-reported ability to walk one-quarter mile) was shown to be an independent predictor of mortality; across the 12- to 16-month follow-up period, mortality rates were 15% for individuals who were unable to walk one-quarter mile at baseline, 4% for those with mobility difficulty, and 2% for those with no mobility limitations. This association remained significant even after adjustments were made for multiple confounders including demographics,

socioeconomic status, chronic conditions, and health behaviors (difficulty walking one-quarter mile, adjusted odds ratio [OR]: 1.57; 95% CI: 1.10– 2.24]; inability to walk one-quarter mile, adjusted OR: 2.73; 95% CI: 1.79–4.15) [3]. Bergland et al. also reported a significant association (hazard ratio [HR]: 1.79; 95% CI: 1.33–2.42 between loss of mobility and all-cause mortality in community-dwelling men and women in Norway. This was significant after adjustment for self-reported health, body mass index (BMI), smoking, and education level (HR: 1.63; 95% CI: 1.20–2.22) for individuals who were fastest on the timed up and go test of mobility compared with those who were slowest) [1].

KEY DETERMINANTS OF MALE MOBILITY

Several modifiable and non-modifiable factors have been reported in the literature that impact bone, muscle, and joint health and can lead to progressive loss of mobility and predispose older men to poor balance, falls, and fractures (**Figure 1**) [4-7]. Risk factors shown to influence mobility include older age, lower physical activity, obesity, strength or balance impairment, long-term use of certain medications, history of smoking, excessive alcohol use, nutritional deficiencies, chronic diseases such as obesity, diabetes mellitus, or arthritis, and low socioeconomic status [8-12]. Despite the known benefits of physical activity, exercise-related injuries can lead to mobility limitation, either directly [9] or indirectly via osteoarthritis [10]. Additionally, in men, the gradual decline in serum testosterone concentrations with advancing age is associated with limitations in mobility [13]. Given the importance of mobility and the plethora of risk factors among elderly men, the objective of this narrative review is to describe elements that are vital to healthy ageing in men and the modifiable risk factors that need to be managed to maintain a long, productive, and independent life

without limitations in mobility [4-7]. Because bone, muscle, and joint health are important modifiable factors that can be relatively easily enhanced to improve mobility, these parameters will be the focus of this review.

MAINTENANCE OF BONE HEALTH

Prevalence and Implications

A decrease in bone strength (bone mass and bone quality) with a consequent increase in bone fragility and risk of fracture is termed osteoporosis [14], the most common metabolic bone disease in humans [15]. Osteoporosis is associated with an increased risk of minimal trauma fractures of the spine, proximal femur, or distal radius [4]. Osteoporosis-related fractures, particularly hip fractures, can result in significant mobility disability; among a cohort of hip fracture patients in the US, the proportion of patients able to walk across a room independently decreased from 75% prefracture to only 15% six months post hip fracture [16]. Although more common in women, the prevalence of osteoporosis in men aged ≥ 50 years is estimated at 4.3% in the US [17], 6.6% in Europe [18], and 5.9% in Australia [19]. Osteoporosis has been categorized as a worldwide epidemic by the International Osteoporosis Foundation (IOF) and prevalence rates are expected to increase dramatically with the ageing population in the coming decades, particularly in Asia. Per the IOF estimates, worldwide, 1 in 5 men aged over 50 years will experience an osteoporotic fracture [20]. By 2050, the worldwide prevalence of hip fracture is projected to increase by 310% in men compared with rates in 1990, and more than half of all osteoporotic hip fractures are expected to occur in Asia [21]. Approximately 20% to 25% of hip fractures occur in men [21]. In a nationwide cohort study of Danish patients, risk of mortality following a hip fracture was found to be substantially higher

among men (37.1%) than women (26.4%) in the first 12 months following a hip fracture (male/female risk ratio 1.4; $p < 0.001$) [22]. Mortality is also higher in men following nonhip minimal trauma fractures [23]. Despite its high prevalence and associated morbidity and increased mortality, osteoporosis in men remains underdiagnosed and undertreated [24].

Risk Factors for Osteoporosis

The risk factors associated with osteoporosis are listed in **Table 1** [4, 25-27]. Among these, lack of weight-bearing exercise, poor calcium intake, vitamin D deficiency, low or high body weight, cigarette smoking, excessive alcohol use, and long-term use of glucocorticoids are common modifiable risk factors [25]. It is now well established that testosterone, adrenal androgens, estrogen, growth hormone, and insulin-like growth factor-1 decline with advancing age, and this decline has been associated with both reduced bone formation and increased bone loss [28]. Among these, testosterone deficiency and glucocorticoid therapy are the most common secondary risk factors for the development of osteoporosis in men [13].

Management of Osteoporosis

Management of osteoporosis includes lifestyle measures and pharmacologic as well as hormonal therapy [15]. According to the National Osteoporosis Foundation, the universal recommendations for lifestyle measures include regular weight-bearing and muscle-strengthening exercises, adequate intake of calcium and vitamin D, cessation of tobacco use, avoidance of excessive alcohol consumption, and treatment of risk factors for falling [15]. While the importance of these interventions

and the need for supplementation changes with age, these lifestyle measures should be maintained throughout life to optimize bone health [25].

A recent systematic review on the effects of exercise on bone mineral density (BMD) [29] found limited positive benefits in controlled clinical trials of exercise training of 6 months or longer in healthy older men (aged ≥ 50 years) who were not being treated with bone-relevant pharmacologic therapy. Of the 6 studies the authors identified as relevant for analysis, 3 studies showed significant improvement in proximal femur BMD, and 3 found no or inconsistent benefits in the exercise groups. Based on the available literature, the authors concluded that it was not possible to recommend specific exercise interventions for older men that would differ from those based on studies in older women. However, promising effects on lumbar spine BMD have been observed from a high-intensity resistance training and impact exercise program in postmenopausal women [30], suggesting higher intensity interventions should be explored in populations at risk of osteoporosis and fracture.

In terms of calcium and vitamin D intake (diet + supplementation), the recommended intakes are 1,000–1,200 mg of calcium per day and 600–800 IU/day of vitamin D for older men [31, 32]. Calcium is required for the mineralization of bone, and presence of vitamin D is required for the absorption of dietary calcium in the gut [33]. A meta-analysis based on 8 clinical trials involving 195 hip fracture events and 2,231 total fracture events among 30,970 community-dwelling and institutionalized middle-aged-to-older adults showed a statistically significant 14% reduction (95% CI: 0.75–0.98) in risk of total fractures and a 39% reduction (95% CI: 0.46–0.82) in risk of hip fractures with calcium + vitamin D supplementation [33]. A larger reduction in risk

was observed in the studies that included institutionalized participants compared with those that involved community-dwelling subjects. Another meta-analysis of studies restricted to community-dwelling adults failed to find a benefit for supplementation with calcium, vitamin D, or the combination [34]. In general, the benefits of calcium and vitamin D supplementation are most consistently evident among older individuals who are institutionalized and other individuals who are vitamin D deficient (serum 25-hydroxyvitamin D <50 nmol/L or <20 ng/mL) [35]. Other analyses have shown that evidence of a benefit is limited to those with baseline 25-hydroxyvitamin D <30 nmol/L [36].

For men with clinically recognized osteoporosis (based on fracture history and/or high fracture risk), pharmacologic treatment with bisphosphonates is recommended to reduce the risk of vertebral fracture [37]. Randomized, controlled trials of bisphosphonates in men have mainly been limited to smaller trials examining their effects on BMD as primary study endpoints [38]. However, one trial with intravenous zoledronic acid showed a 67% reduction in vertebral fractures across a two-year period as a primary study end point [39]. This class of drugs is approved by the US Food and Drug Administration as a first-line treatment for osteoporosis in men [38]. However, although rare, long-term bisphosphonate use (>5 years) can be associated with osteonecrosis of the jaw, atypical subtrochanteric and diaphyseal femur fractures, atrial fibrillation, and esophageal cancer [40]. Treatment with teriparatide (i.e., recombinant human parathyroid hormone [1–34]), is an option for men with severe osteoporosis at high risk of fracture due to primary or hypogonadal osteoporosis or osteoporosis associated with sustained systemic glucocorticoid use [15]. Although teriparatide was associated with a treatment-dependent increase in

the incidence of osteosarcoma in preclinical studies, this has not been observed in humans in postmarketing registries [41]. Nevertheless, the lifetime use of teriparatide is restricted to 18 or 24 months, depending on the country of drug registration [42-44]. Snyder et al. have confirmed a significant positive impact of testosterone therapy on bone density and strength in men with low baseline levels, but larger and longer-duration studies are needed to determine the role of testosterone in fracture prevention [45].

MAINTENANCE OF MUSCLE STRENGTH

Definition and Prevalence of Sarcopenia

Sarcopenia is broadly defined as the “age-associated loss of skeletal muscle mass and function” [5]. In defining sarcopenia, the Foundation for National Institutes of Health (FNIH) recommended using mobility impairment as the clinically relevant functional state to determine meaningful weakness, and they established an FNIH Sarcopenia Project team to develop a robust and validated clinical definition of sarcopenia [46]. However, there is no clear consensus on the definition of sarcopenia, and several definitions are used, including the recently updated European Working Group on Sarcopenia in Older People (EWGSOP) definition [47], which primarily characterizes sarcopenia as low muscle strength; if low muscle quantity or quality and low physical performance are also present, it is categorized as severe. Sarcopenia has also been defined as “a loss of function, defined by walking speed or distance coupled with a loss of muscle mass” [48]. In 2016, sarcopenia received an ICD-10 code, which represents a major step in recognizing this condition as a disease [49]. In a nationally representative sample of older adults (age ≥ 60 years) in the US, the prevalence of sarcopenia among men was 16%, but

increased to 28% when adjusted for BMI [50]. Muscle loss in combination with high levels of adiposity is referred to as sarcopenic obesity [51].

Risks and Causes of Sarcopenia

Sarcopenia is associated with increased risk of osteoporosis, falls, fractures, physical disability, functional decline, metabolic syndrome, and hospitalizations [52-54]. An analysis of a large prospective cohort of 681 community-dwelling middle-aged and older men and women was performed to determine associations between sarcopenia and risk of falls over 5 years [55]. Results from the analysis indicated variations in the association between sarcopenia and functional decline according to sex; men with low muscle mass had poorer muscle function compared with women [55]. Low muscle mass in older adults with sarcopenia has also been identified as a risk factor for metabolic syndrome and type 2 diabetes. A proposed mechanism is that significantly lower skeletal muscle mass results in greater insulin resistance and consequent type 2 diabetes in older patients with sarcopenia [56]. Sarcopenic men who are obese have even poorer outcomes. In a longitudinal study involving elderly subjects, those with sarcopenic obesity, who were predominantly men, were most likely to experience functional declines, disability, and comorbidities compared with lean sarcopenic or nonsarcopenic obese subjects and those with normal body composition [57]. Similarly, recent data from the Concord Health and Ageing in Men Project (CHAMP) study, a large epidemiologic study of ageing in older men (≥ 70 years of age), showed an association between sarcopenic obesity and an increased risk of falls and fractures [58]. Compared with men without sarcopenia or obesity, men with sarcopenic obesity at baseline (defined using the EWGSOP criteria) had significantly higher 2-year fall rates (incidence rate ratio [IRR]; 1.66; 95% CI: 1.16–

2.37), as did individuals with nonsarcopenic obesity (IRR: 1.30; 95% CI: 1.04–1.62) and in those with sarcopenia without obesity (IRR: 1.58; 95% CI: 1.14–2.17). Although no significant association was found between FNIH-defined sarcopenic obesity and fall rates, there was a significantly increased 6-year fracture rate observed in the FNIH-defined sarcopenic obesity group relative to nonsarcopenic obese men (HR for nonsarcopenic obesity vs sarcopenic obesity: 0.44; 95% CI: 0.23–0.86).

In addition to sarcopenia being a key contributor to disability in the elderly, individuals with sarcopenia have a 4-times higher risk of mortality [52]. A meta-analysis of 17 prospective studies observed a 4-times higher risk of mortality in individuals with sarcopenia compared with those without sarcopenia [52]. Older men with sarcopenic obesity have been confirmed to have a higher risk of all-cause mortality compared with well-matched controls in a prospective cohort study [51].

The causes of sarcopenia in elderly men are multifactorial and include declines in testosterone concentrations with age, decreased growth hormone, mitochondrial abnormalities, long-term glucocorticoid treatment, elevated pro-inflammatory cytokines, inactivity, and nutritional deficiencies [59]. It should also be noted that decreases in muscle strength/function are 2–5 times greater than decreases in muscle mass (**Figure 2**) [60, 61] and loss of muscle function significantly outpaces loss of muscle mass during ageing [62], demonstrating that neuromuscular changes beyond muscle atrophy contribute to functional decline. Indeed, increased fat infiltration of muscle is included in the revised EWGSOP definition as an important

component of sarcopenia [47] and a subject we recently reported as being associated with an increased risk for both osteoporosis and falls [63].

Management of Sarcopenia

Exercise, particularly progressive resistance training (PRT), is a well-recognized therapeutic strategy to prevent and reverse sarcopenia. High-velocity PRT is particularly effective at improving lower limb muscle power, a key contributor to mobility [64]. In addition, vitamin D/calcium and essential amino acid protein supplementation have been shown to have beneficial effects [65, 66], although the effects for the latter have been variable across studies [66]. A recent trial suggests that leucine content, rather than total protein content, of supplements may be the primary determinant of myofibrillar protein synthesis [67]. Studies have suggested some additional benefits of combining dietary supplementation with exercise training [52], particularly for protein in conjunction with regular, prolonged PRT (≥ 2 weekly sessions for ≥ 6 weeks) [68]. Omega-3 fatty acid supplementation has been shown to enhance the effects of PRT for improving strength in older women [69], although this effect has not been demonstrated in older men [70]. Creatinine supplementation combined with resistance training increased lean mass in an elderly cohort in a greater magnitude compared with isolated resistance training in a 12-week, double-blind, randomized, parallel-group, placebo-controlled trial, however, the long-term benefits of this intervention needs to be determined [71].

With respect to pharmacological therapy, there are no approved treatments for sarcopenia to date. Testosterone and selective androgen receptor molecules are being used to treat sarcopenia; however, their safety is a concern [59]. Monoclonal antibodies targeting either activin or myostatin, a growth hormone involved in

regulating muscle mass and strength, are also being investigated as potential agents in the treatment of sarcopenia [72]. One such agent, bimagrumab, an activin type II receptor antagonist, has shown efficacy and safety in increasing skeletal muscle mass and strength in community-dwelling older adults with sarcopenia and mobility limitations and increasing walking speed and mobility in those with lower baseline performance. These data provide strong support for the further evaluation and development of this class of agents [73].

MAINTENANCE OF JOINT HEALTH

Definition and Prevalence

Osteoarthritis is the most common chronic condition affecting the joint that can impact all joint tissues including the cartilage, bone, ligaments, and muscles [74].

The range of joint motion in patients with osteoarthritis is strongly correlated with the level of disability; including, walking, sitting, bending, and reclining [75]. In addition to mobility-related disabilities, patients with osteoarthritis suffer with chronic pain, aching, and stiffness and a poor quality of life [76, 77].

In the US, 33% of men in the age group of 55–64 years have a confirmed diagnosis of arthritis, which increases to almost 50% in men 85 years of age and older (**Figure 3**) [78]. Prevalence rates of arthritis and arthritis-attributable activity limitation are projected to progressively increase through the year 2040, with the largest estimated increases occurring in adults over 65 years of age [78]. When comparing differences in prevalence rates based on gender, osteoarthritis has been shown to affect more men than women aged 50 years; however, following menopause, the rate of

osteoarthritis is significantly higher among women, which suggests a sex hormone link in the etiology of the disease [6, 79].

Risk Factors for Osteoarthritis

Osteoarthritis is a multifactorial disease with a number of modifiable and nonmodifiable risk factors. Modifiable risk factors include obesity, muscle strength, physical activity, improper movements, joint injury, and diet, while nonmodifiable risk factors include age, gender, genetics, ethnicity, and joint and/or bone deformities [6]. Individuals with osteoarthritis have a higher risk of falling, which is augmented by increasing age, pain level, and degree of muscle weakness [80].

Management of Osteoarthritis

Several pharmacologic and nonpharmacologic modalities have been recommended for the management of osteoarthritis. With respect to the nonpharmacologic modalities, the American College of Rheumatology guidelines recommend that patients with knee and hip osteoarthritis enroll in an exercise program that includes aerobic, aquatic, and/or resistance exercises [81]. Additionally, dietary changes have been recommended to prevent or manage symptoms. These include maintaining dietary amounts of essential nutrients from foods and/or supplementing beyond recommended dietary allowances with vitamins C (ascorbic acid), D (cholecalciferol), E (tocopherols and tocotrienols), B₃ (niacin), B₁₂ (cobalamin), and folate (folic acid, a B vitamin), minerals boron and zinc, essential fatty acids, and some nonessential phytonutrients [82]. As obesity is one of the important modifiable risk factors of osteoarthritis, weight loss by combined diet and exercise is likely to be an effective strategy in overweight or obese patients with osteoarthritis [83].

Pharmacologic treatments for hip and knee OA include adequate pain relief with intermittent dosing of acetaminophen, oral and topical nonsteroidal anti-inflammatory drugs (NSAIDs), tramadol, and intra-articular corticosteroid injections. Intra-articular hyaluronate injections, duloxetine, and opioids are options for individuals not responding to initial therapy; for adults 75 years of age or older, topical rather than oral NSAIDs should be considered in view of the adverse cardiovascular effects associated with NSAIDs [81]. However, all these therapies are, at best, moderately effective, and maintaining a healthy weight and regular exercise remains the most strongly recommended intervention [81-84].

MAINTENANCE OF BALANCE

Prevalence and Risk Factors

Loss of balance among older individuals results in falls, which in turn, are associated with fractures, soft-tissue injuries, pain, functional impairment, reduced quality of life, hospitalizations, and mortality [7]. According to the US Centers for Disease Control and Prevention, 1 in 4 older individuals (>65 years of age) fall each year and every 19 minutes an elderly person dies from a fall [85]. Consequently, falls should be prevented to avoid debilitating consequences among older adults. To prevent falls, it is important to know the risk factors that makes an individual prone to falls, and these include vitamin D deficiency, impaired strength and balance, visual impairment, use of multiple prescription medications, solitary living, and environmental hazards such as poor lighting, slippery floors, and uneven surfaces [86]. Pain, a common symptom among older adults, has been associated with problems with balance or coordination, fear of falls, and a history of falls [87].

Therefore, fall prevention programs should incorporate effective pain management strategies [87].

Prevention of Falls

Several structured programs have been reported to be effective in preventing falls. One such primary prevention program, Pennsylvania's Healthy Steps for Older Adults (HSOA), comprises balance assessments, education on falls, and referrals for fall assessments [88]. Completion of the HSOA was associated with a 17% reduction in falls after adjustment for fall risk factors [88]. The benefits of another approach called the Lifestyle integrated Functional Exercise program, wherein balance and strength activities are taught over 5 home visits with 2 booster visits, was assessed in a 3-arm, randomized, parallel trial. This study reported a 31% reduction in the rate of falls compared with a control program [89]. A systematic review and meta-analysis of randomized, controlled trials of exercise as a primary intervention for fall prevention in older adults (mean age ≥ 65 years) has reported that exercise programs of higher doses (>3 hours/week) and those that incorporate challenging balance activities are most effective for preventing falls [90]. A recent meta-analysis of 40 randomized, controlled trials of $>20,000$ individuals reported that moderately intensive exercise 2 to 3 times per week significantly decreased the risk of falls and injurious falls but had no effect on fracture risk [91]. Programs that combined balance training and exercise resulted in a 39% reduction in falls (IRR: 0.61; 95% CI: 0.53–0.72) compared with the 21% risk reduction found for exercise programs of any type among community-dwelling older adults (pooled rate ratio: 0.79; 95% CI: 0.73–0.85). The authors found limited evidence available supporting the effect of exercise for fall prevention among older adults living in residential care facilities, after stroke, or

following discharge from the hospital [90]. A 9-month study involving members from the University of Connecticut arm of the Frailty and Injuries: Cooperative Studies of Intervention Techniques (FICSIT) trials concluded that a maintenance program of balance and strength exercises might be a more effective strategy to improve balance and strength in older individuals rather than interventions such as Tai Chi, which have shown some benefits in reducing falls, probably by knee and hip strengthening [92].

To recommend suitable interventions that are feasible to implement in primary care for community-dwelling adults over 65 years of age, the US Preventive Services Task Force (USPSTF) published an evidence review and recommendation statement on interventions to prevent falls [93], which was recently updated [94]. This evidence-based guideline recommends exercise interventions (including supervised individual or group classes and physical therapy) to help prevent falls in older adults. The National Council on Aging has further recommended a number of evidence-based fall-prevention programs, including Otago, A Matter of Balance, Stay Active and Independent for Life, Stepping On, and Fit & Strong [95]. Although earlier recommendations included vitamin D supplementation, the benefits to individuals without osteoporosis or vitamin D deficiencies for fall prevention are unclear [94]. As a result, the USPSTF now recommends against vitamin D supplementation for prevention of falls in all community-dwelling older adults. It should be noted that USPSTF regards vitamin D supplementation in subjects with a deficiency as treatment, and these recommendations do not apply to individuals with a diagnosis of osteoporosis or vitamin D deficiency [94]. However, the Endocrine Society and the National Osteoporosis Foundation recommend consumption of fortified foods and/or

vitamin D supplements to ensure that recommended intake levels are reached [96, 97]. In addition, a fall prevention program could consider individualizing interventions to address specific risks for each patient, such as use of anti-slip shoe devices when walking in slippery conditions, monitoring and adjusting psychotropic medications, vision correction, and pacemaker implantation in patients with cardioinhibitory carotid sinus hypersensitivity [98]. However, these interventions are supported by limited evidence. The evidence review conducted by the USPSTF found that multifactorial interventions customized to the patient based on an assessment of risk have a small benefit for the prevention of falls, and they recommend that such interventions be selectively offered by clinicians only to those at increased risk for falls [94]. Evidence for medication management and other interventions was too limited or heterogeneous to allow for any definitive conclusions.

OVERALL CLINICAL RECOMMENDATIONS FOR PROMOTING MOBILITY AND HEALTHY AGEING IN MEN

Despite the availability of greater socioeconomic facilities and resources, men have a shorter life span than women [99]. Premature mortality among men is often attributed to unhealthy lifestyle choices and lower levels of preventive health care [99, 100]. This combined with the numeric surge in older people presents a critical challenge for public health and highlights the need to specifically improve the health and well-being of older men [100]. In this review, we have focused on discussing various conditions that commonly cause limitations in mobility among older men, including osteoporosis, sarcopenia, osteoarthritis, and balance.

Bone health can be improved by taking relatively simple preventive actions throughout the life span [25]. Preventive care should focus on regular weight-bearing

and muscle-strengthening exercises, adequate intake of protein, calcium, and vitamin D, maintaining a healthy weight, cessation of tobacco use, avoidance of excessive alcohol consumption, and treatment of risk factors for falling [15]. While the importance of these interventions and the need for supplementation change with age, these lifestyle measures should be maintained throughout life to optimize bone health [25].

Men with strong masculinity beliefs are less likely to receive preventive care [99] and often have difficulty talking about their health problems when they occur, which frequently serves as a barrier to help-seeking behavior [101]. Poor health has been shown to be one of the most important barriers to participating in physical activity, in particular for older men (≥ 80 years) [102]. For men in particular, aches and pains, which are frequent consequences of physical activity, are often a barrier to further physical activity for men who start these activities aggressively and subsequently become disincentivized to participate. Additionally, social isolation is common among older men, particularly among those who experience mood or cognitive problems or who live alone [100], which has been shown to be an independent risk factor for not participating in physical activities [102]. Potential motivators for physical activity include task-related factors, such as meaningful, enjoyable, and routine activities to participate in, individual-level factors, including a group of peers as well as younger friends, and environmental factors such as places to rest and family support) [101]. A recent study reported that older adults should receive adequate background information about the rationale for performing physical exercise and clarification that an exercise program will be safe and provide benefits to various aspects of their lives, including mobility, independence, and quality of life, and will not do harm [103].

Considering the benefits of engaging in community programs and men's relatively lower rate of involvement, there is a strong need to develop community program that target older men in particular, such as "Men's Sheds" [100]. This program originated in Australia to create a positive impact on social engagement, adult education, and health and has now expanded to several other countries globally, enabling men to socialize and participate in learning activities. Such programs should be made available to all older men and should include educational programs and lifestyle interventions to support desirable lifestyle behaviors at all stages of life in healthy individuals [104].

SUMMARY

Age-related changes in bones, muscles, and joints, as well as declines in balance, can impact mobility in older men. There needs to be a coordinated approach among healthcare providers, who should work closely with older men and/or their caregivers to provide and re-evaluate evidence-based and effective interventions to optimize bone, muscle, and joint health. This is required to maintain strength, balance, and flexibility, which are essential for independent mobility, a key component of healthy ageing. Additionally, interventions involving exercise and nutrition, and specifically supporting participation in men, should be initiated as early as possible to prevent and/or reverse the progressive deterioration in bone, muscle, and joint health with ageing and subsequently, to delay the onset of these common and chronic diseases that limit mobility and prevent healthy ageing. Barriers specific to males have been identified, including a tendency to have difficulty discussing health-related concerns,

and these should be the focus of interventions to engage men in health-promoting behaviors that are relevant to improving bone, muscle, and joint health.

REFERENCES

1. Bergland A, Jorgensen L, Emaus N, Strand BH (2017) Mobility as a predictor of all-cause mortality in older men and women: 11.8 year follow-up in the Tromso study. *BMC Health Serv Res* 17:22. <https://doi.org/10.1186/s12913-016-1950-0>.
2. Musich S, Wang SS, Ruiz J, Hawkins K, Wicker E (2018) The impact of mobility limitations on health outcomes among older adults. *Geriatr Nurs* 39:162-169. <https://doi.org/10.1016/j.gerinurse.2017.08.002>.
3. Hardy SE, Kang Y, Studenski SA, Degenholtz HB (2011) Ability to walk 1/4 mile predicts subsequent disability, mortality, and health care costs. *J Gen Intern Med* 26:130-135. <https://doi.org/10.1007/s11606-010-1543-2>.
4. Champion JM, Maricic MJ (2003) Osteoporosis in men. *Am Fam Physician* 67:1521-1526.
5. Fielding RA, Vellas B, Evans WJ, et al. (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. *J Am Med Dir Assoc* 12:249-256. <https://doi.org/10.1016/j.jamda.2011.01.003>.
6. Musumeci G, Aiello FC, Szychlinska MA, Di Rosa M, Castrogiovanni P, Mobasher A (2015) Osteoarthritis in the XXIst century: risk factors and behaviours that influence disease onset and progression. *Int J Mol Sci* 16:6093-6112. <https://doi.org/10.3390/ijms16036093>.
7. Sanders KM, Lim K, Stuart AL, Macleod A, Scott D, Nicholson GC, Busija L (2017) Diversity in fall characteristics hampers effective prevention: the precipitants, the environment, the fall and the injury. *Osteoporos Int* 28:3005-3015. <https://doi.org/10.1007/s00198-017-4145-6>.

8. Brown CJ, Flood KL (2013) Mobility limitation in the older patient: a clinical review. *JAMA* 310:1168-1177. <https://doi.org/10.1001/jama.2013.276566>.
9. Iezzoni LI, McCarthy EP, Davis RB, Siebens H (2001) Mobility difficulties are not only a problem of old age. *J Gen Intern Med* 16:235-243.
10. Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW, Kelly-Hayes M, Wolf PA, Kreger BE, Kannel WB (1994) The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. *Am J Public Health* 84:351-358.
11. Vincent HK, Vincent KR, Lamb KM (2010) Obesity and mobility disability in the older adult. *Obes Rev* 11:568-579. <https://doi.org/10.1111/j.1467-789X.2009.00703.x>.
12. Yeom HA, Fleury J, Keller C (2008) Risk factors for mobility limitation in community-dwelling older adults: a social ecological perspective. *Geriatr Nurs* 29:133-140. <https://doi.org/10.1016/j.gerinurse.2007.07.002>.
13. Ebeling PR (2010) Androgens and osteoporosis. *Curr Opin Endocrinol Diabetes Obes* 17:284-292. <https://doi.org/10.1097/MED.0b013e328339658c>.
14. Compston J, Cooper A, Cooper C, et al. (2017) UK clinical guideline for the prevention and treatment of osteoporosis. *Arch Osteoporos* 12:43. <https://doi.org/10.1007/s11657-017-0324-5>.
15. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int* 25:2359-2381. <https://doi.org/10.1007/s00198-014-2794-2>.
16. Marottoli RA, Berkman LF, Cooney LM, Jr. (1992) Decline in physical function following hip fracture. *J Am Geriatr Soc* 40:861-866.

17. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. *J Bone Miner Res* 29:2520-2526.
<https://doi.org/10.1002/jbmr.2269>.
18. Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos* 8:136. <https://doi.org/10.1007/s11657-013-0136-1>.
19. Henry MJ, Pasco JA, Nicholson GC, Kotowicz MA (2011) Prevalence of osteoporosis in Australian men and women: Geelong Osteoporosis Study. *Med J Aust* 195:321-322.
20. (2014) The global burden of osteoporosis: a factsheet. International Osteoporosis Foundation.
<https://www.iofbonehealth.org/sites/default/files/media/PDFs/Fact%20Sheets/2014-factsheet-osteoporosis-A4.pdf>. Accessed February 12, 2019
21. International Osteoporosis Foundation (2017) Osteoporosis Facts and Statistics. International Osteoporosis Foundation.
<https://www.iofbonehealth.org/facts-statistics>. Accessed February 12, 2019
22. Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B (2010) Excess mortality in men compared with women following a hip fracture. National analysis of comedICATIONS, comorbidity and survival. *Age Ageing* 39:203-209.
<https://doi.org/10.1093/ageing/afp221>.

23. Chen W, Simpson JM, March LM, Blyth FM, Bliuc D, Tran T, Nguyen TV, Eisman JA, Center JR (2018) Comorbidities only account for a small proportion of excess mortality after fracture: A record linkage study of individual fracture types. *J Bone Miner Res* 33:795-802.
<https://doi.org/10.1002/jbmr.3374>.
24. Feldstein AC, Nichols G, Orwoll E, Elmer PJ, Smith DH, Herson M, Aickin M (2005) The near absence of osteoporosis treatment in older men with fractures. *Osteoporos Int* 16:953-962. <https://doi.org/10.1007/s00198-005-1950-0>.
25. Ebeling PR, Daly RM, Kerr DA, Kimlin MG (2013) Building healthy bones throughout life: an evidence-informed strategy to prevent osteoporosis in Australia. *Med J Aust* 199:S1.
26. (2018) HIV and osteoporosis. US Department of Health and Human Services. <https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/22/62/hiv-and-osteoporosis>. Accessed February 12, 2019
27. Rossini M, Zanotti R, Viapiana O, et al. (2014) Bone involvement and osteoporosis in mastocytosis. *Immunol Allergy Clin North Am* 34:383-396.
<https://doi.org/10.1016/j.iac.2014.01.011>.
28. Seeman E (1999) Osteoporosis in men. *Osteoporos Int* 9 Suppl 2:S97-s110.
29. Kemmler W, Shojaa M, Kohl M, von Stengel S (2018) Exercise effects on bone mineral density in older men: a systematic review with special emphasis on study interventions. *Osteoporos Int* 29:1493-1504.
<https://doi.org/10.1007/s00198-018-4482-0>.
30. Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR (2018) High-intensity resistance and impact training improves bone mineral density

- and physical function in postmenopausal women with osteopenia and osteoporosis: The LIFTMOR randomized controlled trial. *J Bone Miner Res* 33:211-220. <https://doi.org/10.1002/jbmr.3284>.
31. National Institute of Health (2016) Calcium Fact Sheet for Health Professionals. National Institute of Health Office of Dietary Supplements. <https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/>. Accessed February 12, 2019
 32. (2016) Vitamin D fact sheet for health professionals. National Institutes of Health. <https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/>. Accessed February 12, 2019
 33. Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, LeBoff MS, Liu S, Looker AC, Wallace TC, Wang DD (2016) Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation [published erratum and additional analyses appear in *Osteoporos Int*. 2016;27(8):2643-2646] *Osteoporos Int* 27:367-376. <https://doi.org/10.1007/s00198-015-3386-5>.
 34. Zhao JG, Zeng XT, Wang J, Liu L (2017) Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: A systematic review and meta-analysis. *JAMA* 318:2466-2482. <https://doi.org/10.1001/jama.2017.19344>.
 35. Lips P, Gielen E, van Schoor NM (2014) Vitamin D supplements with or without calcium to prevent fractures. *Bonekey Rep* 3:512. <https://doi.org/10.1038/bonekey.2014.7>.
 36. Macdonald HM, Reid IR, Gamble GD, Fraser WD, Tang JC, Wood AD (2018) 25-Hydroxyvitamin D threshold for the effects of vitamin D supplements on

- bone density: Secondary analysis of a randomized controlled trial. *J Bone Miner Res* 33:1464-1469. <https://doi.org/10.1002/jbmr.3442>.
37. Qaseem A, Forciea MA, McLean RM, Denberg TD (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the American College of Physicians. *Ann Intern Med* 166:818-839. <https://doi.org/10.7326/m15-1361>.
 38. Sim LW, Ebeling PR (2013) Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence. *Ther Adv Musculoskelet Dis* 5:259-267. <https://doi.org/10.1177/1759720x13500861>.
 39. Boonen S, Reginster JY, Kaufman JM, et al. (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. *N Engl J Med* 367:1714-1723. <https://doi.org/10.1056/NEJMoa1204061>.
 40. Brown JP, Morin S, Leslie W, et al. (2014) Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. *Can Fam Physician* 60:324-333.
 41. Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. *J Bone Miner Res* 27:2429-2437. <https://doi.org/10.1002/jbmr.1768>.
 42. (2017) Forsteo [summary of product characteristics]. Eli Lilly Nederland, Utrecht, The Netherlands
 43. (2016) Forteo [package insert]. Eli Lilly and Company, Indianapolis, IN
 44. (2015) Forteo AU [package insert]. Eli Lilly Australia Pty Limited, West Ryde, NSW, Australia

45. Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. (2017) Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: A controlled clinical trial. *JAMA Intern Med* 177:471-479. <https://doi.org/10.1001/jamainternmed.2016.9539>.
46. Studenski SA, Peters KW, Alley DE, et al. (2014) The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. *J Gerontol A Biol Sci Med Sci* 69:547-558. <https://doi.org/10.1093/gerona/glu010>.
47. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. (2019) Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 48:16-31. <https://doi.org/10.1093/ageing/afy169>.
48. Morley JE, von Haehling S, Anker SD (2014) Are we closer to having drugs to treat muscle wasting disease? *J Cachexia Sarcopenia Muscle* 5:83-87. <https://doi.org/10.1007/s13539-014-0149-7>.
49. Cao L, Morley JE (2016) Sarcopenia is recognized as an independent condition by an International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) code. *J Am Med Dir Assoc* 17:675-677. <https://doi.org/10.1016/j.jamda.2016.06.001>.
50. Batsis JA, Mackenzie TA, Lopez-Jimenez F, Bartels SJ (2015) Sarcopenia, sarcopenic obesity, and functional impairments in older adults: National Health and Nutrition Examination Surveys 1999-2004. *Nutr Res* 35:1031-1039. <https://doi.org/10.1016/j.nutres.2015.09.003>.
51. Atkins JL, Whincup PH, Morris RW, Lennon LT, Papacosta O, Wannamethee SG (2014) Sarcopenic obesity and risk of cardiovascular disease and

- mortality: a population-based cohort study of older men. *J Am Geriatr Soc* 62:253-260. <https://doi.org/10.1111/jgs.12652>.
52. Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyere O (2017) Health outcomes of sarcopenia: A systematic review and meta-analysis. *PLoS One* 12:e0169548. <https://doi.org/10.1371/journal.pone.0169548>.
 53. Lee J, Hong YP, Shin HJ, Lee W (2016) Associations of sarcopenia and sarcopenic obesity with metabolic syndrome considering both muscle mass and muscle strength. *J Prev Med Public Health* 49:35-44. <https://doi.org/10.3961/jpmph.15.055>.
 54. Verschueren S, Gielen E, O'Neill TW, et al. (2013) Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men. *Osteoporos Int* 24:87-98. <https://doi.org/10.1007/s00198-012-2057-z>.
 55. Scott D, Hayes A, Sanders KM, Aitken D, Ebeling PR, Jones G (2014) Operational definitions of sarcopenia and their associations with 5-year changes in falls risk in community-dwelling middle-aged and older adults. *Osteoporos Int* 25:187-193. <https://doi.org/10.1007/s00198-013-2431-5>.
 56. Scott D, de Courten B, Ebeling PR (2016) Sarcopenia: a potential cause and consequence of type 2 diabetes in Australia's ageing population? *Med J Aust* 205:329-333.
 57. Baumgartner RN, Wayne SJ, Waters DL, Janssen I, Gallagher D, Morley JE (2004) Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. *Obes Res* 12:1995-2004. <https://doi.org/10.1038/oby.2004.250>.
 58. Scott D, Seibel M, Cumming R, Naganathan V, Blyth F, Le Couteur DG, Handelsman DJ, Waite LM, Hirani V (2017) Sarcopenic obesity and its

- temporal associations with changes in bone mineral density, incident falls, and fractures in older men: The Concord Health and Ageing in Men Project. *J Bone Miner Res* 32:575-583. <https://doi.org/10.1002/jbmr.3016>.
59. Morley JE (2012) Sarcopenia in the elderly. *Fam Pract* 29 Suppl 1:i44-i48. <https://doi.org/10.1093/fampra/cmr063>.
60. Hayashida I, Tanimoto Y, Takahashi Y, Kusabiraki T, Tamaki J (2014) Correlation between muscle strength and muscle mass, and their association with walking speed, in community-dwelling elderly Japanese individuals. *PLoS One* 9:e111810. <https://doi.org/10.1371/journal.pone.0111810>.
61. Delmonico MJ, Harris TB, Visser M, et al. (2009) Longitudinal study of muscle strength, quality, and adipose tissue infiltration. *Am J Clin Nutr* 90:1579-1585. <https://doi.org/10.3945/ajcn.2009.28047>.
62. Hughes VA, Frontera WR, Wood M, Evans WJ, Dallal GE, Roubenoff R, Fiatarone Singh MA (2001) Longitudinal muscle strength changes in older adults: influence of muscle mass, physical activity, and health. *J Gerontol A Biol Sci Med Sci* 56:B209-217.
63. Scott D, Johansson J, McMillan LB, Ebeling PR, Nordstrom A, Nordstrom P (2018) Mid-calf skeletal muscle density and its associations with physical activity, bone health and incident 12-month falls in older adults: The Healthy Ageing Initiative. *Bone* 120:446-451. <https://doi.org/10.1016/j.bone.2018.12.004>.
64. Bean JF, Kiely DK, LaRose S, O'Neill E, Goldstein R, Frontera WR (2009) Increased velocity exercise specific to task training versus the National Institute on Aging's strength training program: changes in limb power and

- mobility. *J Gerontol A Biol Sci Med Sci* 64:983-991.
<https://doi.org/10.1093/gerona/glp056>.
65. Mithal A, Bonjour JP, Boonen S, et al. (2013) Impact of nutrition on muscle mass, strength, and performance in older adults. *Osteoporos Int* 24:1555-1566. <https://doi.org/10.1007/s00198-012-2236-y>.
66. Beaudart C, Rabenda V, Simmons M, Geerinck A, Araujo De Carvalho I, Reginster JY, Amuthavalli Thiyagarajan J, Bruyere O (2018) Effects of protein, essential amino acids, B-hydroxy B-methylbutyrate, creatine, dehydroepiandrosterone and fatty acid supplementation on muscle mass, muscle strength and physical performance in older people aged 60 years and over. A systematic review of the literature. *J Nutr Health Aging* 22:117-130. <https://doi.org/10.1007/s12603-017-0934-z>.
67. Devries MC, McGlory C, Bolster DR, Kamil A, Rahn M, Harkness L, Baker SK, Phillips SM (2018) Leucine, not total protein, content of a supplement is the primary determinant of muscle protein anabolic responses in healthy older women. *J Nutr* 148:1088-1095. <https://doi.org/10.1093/jn/nxy091>.
68. Cermak NM, Res PT, de Groot LC, Saris WH, van Loon LJ (2012) Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. *Am J Clin Nutr* 96:1454-1464. <https://doi.org/10.3945/ajcn.112.037556>.
69. Rodacki CL, Rodacki AL, Pereira G, Naliwaiko K, Coelho I, Pequito D, Fernandes LC (2012) Fish-oil supplementation enhances the effects of strength training in elderly women. *Am J Clin Nutr* 95:428-436. <https://doi.org/10.3945/ajcn.111.021915>.

70. Da Boit M, Sibson R, Sivasubramaniam S, et al. (2017) Sex differences in the effect of fish-oil supplementation on the adaptive response to resistance exercise training in older people: a randomized controlled trial. *Am J Clin Nutr* 105:151-158. <https://doi.org/10.3945/ajcn.116.140780>.
71. Pinto CL, Botelho PB, Carneiro JA, Mota JF (2016) Impact of creatine supplementation in combination with resistance training on lean mass in the elderly. *J Cachexia Sarcopenia Muscle* 7:413-421. <https://doi.org/10.1002/jcsm.12094>.
72. Camporez JP, Petersen MC, Abudukadier A, Moreira GV, Jurczak MJ, Friedman G, Haqq CM, Petersen KF, Shulman GI (2016) Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice. *Proc Natl Acad Sci U S A* 113:2212-2217. <https://doi.org/10.1073/pnas.1525795113>.
73. Rooks D, Praestgaard J, Hariry S, Laurent D, Petricoul O, Perry RG, Lach-Trifilieff E, Roubenoff R (2017) Treatment of sarcopenia with bimagrumab: Results from a phase II, randomized, controlled, proof-of-concept study. *J Am Geriatr Soc* 65:1988-1995. <https://doi.org/10.1111/jgs.14927>.
74. Osteoarthritis Research Society International (2013) What Is Osteoarthritis? Osteoarthritis Research Society International. <https://www.oarsi.org/what-osteoarthritis>. Accessed February 12, 2019
75. Steultjens MP, Dekker J, van Baar ME, Oostendorp RA, Bijlsma JW (2000) Range of joint motion and disability in patients with osteoarthritis of the knee or hip. *Rheumatology (Oxford)* 39:955-961.

76. Neogi T (2013) The epidemiology and impact of pain in osteoarthritis. *Osteoarthritis Cartilage* 21:1145-1153.
<https://doi.org/10.1016/j.joca.2013.03.018>.
77. Laslett LL, Quinn SJ, Winzenberg TM, Sanderson K, Cicuttini F, Jones G (2012) A prospective study of the impact of musculoskeletal pain and radiographic osteoarthritis on health related quality of life in community dwelling older people. *BMC Musculoskelet Disord* 13:168.
<https://doi.org/10.1186/1471-2474-13-168>.
78. Hootman JM, Helmick CG, Barbour KE, Theis KA, Boring MA (2016) Updated projected prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation among US adults, 2015-2040. *Arthritis Rheumatol* 68:1582-1587. <https://doi.org/10.1002/art.39692>.
79. Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G (2005) A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. *Osteoarthritis Cartilage* 13:769-781.
<https://doi.org/10.1016/j.joca.2005.04.014>.
80. Zasadzka E, Borowicz AM, Roszak M, Pawlaczyk M (2015) Assessment of the risk of falling with the use of timed up and go test in the elderly with lower extremity osteoarthritis. *Clin Interv Aging* 10:1289-1298.
<https://doi.org/10.2147/cia.s86001>.
81. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)* 64:465-474.

82. Melanson KJ (2007) Diet, nutrition and osteoarthritis. *Am J Lifestyle Med* 1:260-263. <https://doi.org/10.1177/1559827607302033>.
83. Miller GD, Nicklas BJ, Davis C, Loeser RF, Lenchik L, Messier SP (2006) Intensive weight loss program improves physical function in older obese adults with knee osteoarthritis. *Obesity (Silver Spring, Md)* 14:1219-1230. <https://doi.org/10.1038/oby.2006.139>.
84. Fransen M, McConnell S, Harmer AR, Van der Esch M, Simic M, Bennell KL (2015) Exercise for osteoarthritis of the knee: a Cochrane systematic review. *Br J Sports Med* 49:1554-1557. <https://doi.org/10.1136/bjsports-2015-095424>.
85. (2018) Falls prevention facts. National Council on Aging. <https://www.ncoa.org/news/resources-for-reporters/get-the-facts/falls-prevention-facts/>. Accessed February 12, 2019
86. Fraix M (2012) Role of the musculoskeletal system and the prevention of falls. *J Am Osteopath Assoc* 112:17-21.
87. Patel KV, Phelan EA, Leveille SG, Lamb SE, Missikpode C, Wallace RB, Guralnik JM, Turk DC (2014) High prevalence of falls, fear of falling, and impaired balance in older adults with pain in the United States: findings from the 2011 National Health and Aging Trends Study. *J Am Geriatr Soc* 62:1844-1852. <https://doi.org/10.1111/jgs.13072>.
88. Albert SM, King J, Boudreau R, Prasad T, Lin CJ, Newman AB (2014) Primary prevention of falls: effectiveness of a statewide program. *Am J Public Health* 104:e77-84. <https://doi.org/10.2105/ajph.2013.301829>.
89. Clemson L, Fiatarone Singh MA, Bundy A, Cumming RG, Manollaras K, O'Loughlin P, Black D (2012) Integration of balance and strength training into

- daily life activity to reduce rate of falls in older people (the LiFE study): randomised parallel trial. *BMJ* 345:e4547. <https://doi.org/10.1136/bmj.e4547>.
90. Sherrington C, Michaleff ZA, Fairhall N, Paul SS, Tiedemann A, Whitney J, Cumming RG, Herbert RD, Close JCT, Lord SR (2017) Exercise to prevent falls in older adults: an updated systematic review and meta-analysis. *Br J Sports Med* 51:1750-1758. <https://doi.org/10.1136/bjsports-2016-096547>.
 91. de Souto Barreto P, Rolland Y, Vellas B, Maltais M (2018) Association of long-term exercise training with risk of falls, fractures, hospitalizations, and mortality in older adults: A systematic review and meta-analysis. *JAMA Intern Med* <https://doi.org/10.1001/jamainternmed.2018.5406>.
 92. Wolfson L, Whipple R, Derby C, Judge J, King M, Amerman P, Schmidt J, Smyers D (1996) Balance and strength training in older adults: intervention gains and Tai Chi maintenance. *J Am Geriatr Soc* 44:498-506.
 93. Moyer VA (2012) Prevention of falls in community-dwelling older adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 157:197-204. <https://doi.org/10.7326/0003-4819-157-3-201208070-00462>.
 94. Grossman DC, Curry SJ, Owens DK, et al. (2018) Interventions to prevent falls in community-dwelling older adults: US Preventive Services Task Force recommendation statement. *JAMA* 319:1696-1704. <https://doi.org/10.1001/jama.2018.3097>.
 95. (2019) Evidence-based falls prevention programs. National Council on Aging. <https://www.ncoa.org/healthy-aging/falls-prevention/falls-prevention-programs-for-older-adults-2/>. Accessed April 9, 2019
 96. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of

- vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 96:1911-1930. <https://doi.org/jc.2011-0385> [pii];10.1210/jc.2011-0385 [doi].
97. (2018) Calcium and Vitamin D: What You Need to Know. National Osteoporosis Foundation. <https://www.nof.org/patients/treatment/calciumvitamin-d/>. Accessed March 18, 2019
 98. Balzer K, Bremer M, Schramm S, Luhmann D, Raspe H (2012) Falls prevention for the elderly. *GMS Health Technol Assess* 8:Doc01. <https://doi.org/10.3205/hta000099>.
 99. Springer KW, Mouzon DM (2011) "Macho men" and preventive health care: implications for older men in different social classes. *J Health Soc Behav* 52:212-227. <https://doi.org/10.1177/0022146510393972>.
 100. Milligan C, Neary D, Payne S, Hanratty B, Irwin P, Dowrick C (2016) Older men and social activity: a scoping review of men's sheds and other gendered interventions. *Ageing Soc* 36:895-923.
 101. Bredland EL, Soderstrom S, Vik K (2018) Challenges and motivators to physical activity faced by retired men when ageing: a qualitative study. *BMC Public Health* 18:627. <https://doi.org/10.1186/s12889-018-5517-3>.
 102. Moschny A, Platen P, Klaassen-Mielke R, Trampisch U, Hinrichs T (2011) Barriers to physical activity in older adults in Germany: a cross-sectional study. *Int J Behav Nutr Phys Act* 8:121. <https://doi.org/10.1186/1479-5868-8-121>.
 103. Simmonds BAJ, Hannam KJ, Fox KR, Tobias JH (2016) An exploration of barriers and facilitators to older adults' participation in higher impact physical

activity and bone health: a qualitative study. *Osteoporos Int* 27:979-987.

<https://doi.org/10.1007/s00198-015-3376-7>.

104. Ebeling PR, Daly RM, Kerr DA, Kimlin MG (2013) An evidence-informed strategy to prevent osteoporosis in Australia. *Med J Aust* 198:90-91.

Table 1: Risk Factors for Osteoporosis in Men [4, 25-27]

High-risk causes	History of nontraumatic fracture (hip, vertebrae, or wrist) Glucocorticoid use of 5 mg or more per day for >6 months Hypogonadism (glucocorticoid-induced or following orchiectomy) Hyperparathyroidism Lack of weight-bearing exercise Poor calcium intake Vitamin D deficiency Low or high BMI Excess alcohol consumption Tobacco use
------------------	--

<p>Medium-risk or infrequent causes</p>	<p>Anticonvulsant drug use (phenytoin or phenobarbital)</p> <p>Rheumatoid or other inflammatory arthritis</p> <p>Multiple myeloma or lymphoma</p> <p>Hypothyroidism or hyperthyroidism</p> <p>Conditions associated with increased risk of falling (nursing home residence, prior fall, gait disorder, dementia, or hemiparesis)</p> <p>Family history of osteoporosis</p> <p>Cushing's disease</p> <p>Chronic liver or kidney disease</p> <p>HIV and its treatment</p> <p>Pernicious anemia</p> <p>Gastric resection</p> <p>Mastocytosis</p>
---	---

BMI, body mass index; HIV, human immunodeficiency virus.

FIGURE CAPTIONS

Fig. 1 Key determinants of male mobility [4-7]

Fig. 2 Comparison of Knee Extension Strength and Leg Muscle Mass in Men 65–74 Years of Age versus ≥ 75 Years of Age [60]

^a $P < 0.01$ between age groups.

Fig. 3 Prevalence of Arthritis and Attributable Activity Limitation [78]